An interventional study of Collaborative Care and Enhanced usual Care in Hepatocellular Carcinoma, Primary Liver Cancer and Bile Duct Cancer, sponsored by University of Pittsburgh. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.
Sponsored by University of Pittsburgh · Not applicable, Interventional, and Supportive care
The purpose of this study is to test the efficacy of a collaborative care intervention to manage cancer-related symptoms and improve health related quality of life in patients diagnosed with hepatobiliary carcinoma.
The study is a collaborative care intervention designed to reduce pain, fatigue, and depressive symptoms and improve overall health related quality of life.
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's enrollment of 261 is above the median of 45 across 5,170 interventional studies indexed under Carcinoma.
Browse Carcinoma studies →University of Pittsburgh is the lead sponsor of 1,385 studies on the registry; 167 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Care coordinator facilitates the assessment and treatment of cancer-related symptoms
Other: Collaborative Care
Upon evaluation of symptoms the patient will be referred for further assessment or treatment if indicated
Other: Enhanced usual Care
Collaborative care intervention to manage cancer-related symptoms
Depression
Center for Epidemiological Studies-Depression scale
Time frame: Change from baseline at 6 and 12 months
Fatigue
Functional Assessment of Cancer Therapy-Fatigue
Time frame: Change from baseline at 6 and 12 months
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Pittsburgh